This feature highlights changes in clinical trial organizations’ personnel.

Aeterna Zentaris

Michael Teifel, former research and development leader at Cleara Biotech, has been named senior vice president of nonclinical development and chief scientific officer at Aeterna Zentaris.

Azitra

Synthetic biology company Azitra has hired Francisco Salva to serve as its new CEO. Salva previously served as CEO of Complexa.

Carmine Therapeutics

Carmine Therapeutics has appointed Don Haut to CEO. Previously, Haut served as chief business officer at AskBio.

CatalYm

CatalYm has hired Phil L’Huillier to helm the company as its new CEO. L’Huillier previously served as head of the European innovation hub and business development at MSD, formerly known as Merck and Co. in North America.

Codagenix

Johanna Kaufmann, former scientific director of immuno-oncology at GlaxoSmithKline, has been named the new executive vice president of oncology at Codagenix.

Engitix Therapeutics

Mike Burbridge has been named the new vice president of oncology and immuno-oncology at Engitix Therapeutics. Burbridge is the former program director of external innovation at Servier Centre for Therapeutic Innovation in Oncology.

Genespire

Julianne Smith has been named chief development officer at gene therapy company Genespire. Smith is the former vice president of translational sciences at Cellectis. Genespire has also appointed Smaragda Angelidou to head of chemistry, manufacturing and controls. Angelidou most recently served as senior director of tech transfer and product delivery projects at Autolus.

Himalaya Therapeutics

Himalaya Therapeutics has appointed Howe Li to chief medical officer. Previously, Li served as CEO of Tigermed-IntelliPV and currently serves as CEO of DeltaMed.

Invectys

Clinical-stage amino therapy company Invectys has appointed Praveen Tyle to president and CEO. Previously, Tyle served as executive vice president for research and development at Lexicon Pharmaceuticals.

Isosceles Pharmaceuticals

William Humphries, former president of Ortho Dermatologics, has been named the new CEO of Isosceles Pharmaceuticals.

Jaguar Gene Therapy

Jaguar Gene Therapy has appointed Joseph McIntosh to chief medical officer. McIntosh previously served as chief medical officer at Aruvant Sciences.

KalVista Pharmaceuticals

Paul Audhya has been named chief medical officer at KalVista Pharmaceuticals. Audhya is the former senior vice president of global medical affairs at Arena Pharmaceuticals.

Karyopharm Therapeutics

Richard Paulson has taken over Karyopharm Therapeutics as its newest CEO. Paulson was formerly the executive vice president of Ipsen Pharmaceuticals and CEO of Ipsen North America.

Kyowa Kirin North America

Ernesto Aycardi, former chief medical officer at Xenon Pharmaceuticals, has been named chief development officer at Kyowa Kirin North America (KKNA). KKNA also recently named Eslie Dennis the company’s new chief medical officer. Dennis previously served as vice president and head of global medical affairs at Roche Tissue Diagnostics.

MOMA Therapeutics

MOMA Therapeutics has hired Peter Hammerman to take on the chief scientific officer role. Hammerman previously served as global head of oncology translational research at Novartis Institutes for BioMedical Research.

Myeloid Therapeutics

Myeloid Therapeutics has named Bruce McCreedy the company’s new chief scientific officer. McCreedy formerly served as senior vice president of cell therapy and immuno-oncology research at Precision Biosciences.

Synthekine

Naiyer Rizvi has been appointed chief medical officer at Synthekine. Previously, Rizvi was Price Family professor of medicine, director of thoracic oncology and co-director of cancer immunotherapy at Columbia University Medical Center.

Telix Pharmaceuticals

Telix Pharmaceuticals has hired Richard Valeix to take on the role of president of Europe, Middle East and Africa (EMEA). Valeix previously served as general manager for France, Switzerland, Belgium, Netherlands and Luxembourg as well as global head of marketing and sales for Novartis’ Advanced Accelerator Applications.

Theseus Pharmaceuticals

Tim Clackson has been named CEO of Theseus Pharmaceuticals. Clackson is the former president and chief technology officer at Xilio Therapeutics.

Verge Genomics

Verge Genomics has hired Robert Scannevin to take on the role of chief scientific officer. Scannevin previously served as head of research at Yumanity Therapeutics.